MedTrace Logo

Azithromycin Treatment for the Airway Microbiome in Asthma

NCT03736629 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2023-08-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study to determine whether the bacteria inside the lungs of people with asthma can be modified (changed) if they are given an antibiotic and if this change is associated with an improvement in asthma symptoms.

Conditions

  • Asthma Chronic

Interventions

DRUG

Azithromycin

8 weeks of Azithromycin (250 mg) once daily by mouth

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Steve White, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2021-03-01
Completion
2022-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03736629 on ClinicalTrials.gov